PharmaMar, a Spain-based company focused on oncology, announced that its proposal to file for accelerated approval for its new drug application (NDA) for lurbinectedin monotherapy for the treatment of second-line small cell lung cancer (SCLC) was accepted by FDA. The NDA filing is anticipated foOriginal Article
You may also like
FDA Approves SpringWorks Therapeutics Treatment for...
ADVANCEMENTS IN GLP-1 ANALOG FORMULATION DEVELOPMENT:...
Axplora Announces €50 Million Investment in GLP-1...
Drug Digest: Advances in Small-Molecule Manufacturing
Navigating Drug Development: The Critical Role of...
MMS Acquires Exploristics and Its Flagship Modeling...
About the author
David Miller
a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.